Telaprevir in Genotype 3 HCV

Summary

Telaprevir in Genotype 3 HCV is a clinical trial^[1].

Key Facts

• Telaprevir in Genotype 3 HCV is in the country of United Kingdom^[2].
• Telaprevir in Genotype 3 HCV's instance of is recorded as clinical trial^[3].
• Telaprevir in Genotype 3 HCV's start time is recorded as +2014-04-30T00:00:00Z^[4].
• Telaprevir in Genotype 3 HCV's end time is recorded as +2015-06-30T00:00:00Z^[5].
• Telaprevir in Genotype 3 HCV's contributor to the creative work or subject is recorded as St George's University Hospitals NHS Foundation Trust^[6].
• Telaprevir in Genotype 3 HCV's sponsor is recorded as Queen Mary University of London^[7].
• Telaprevir in Genotype 3 HCV's main subject is recorded as hepatitis C^[8].
• Telaprevir in Genotype 3 HCV's number of participants is recorded as {'unit': '1', 'amount': '+30'}^[9].
• Telaprevir in Genotype 3 HCV's title is recorded as Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin^[10].
• Telaprevir in Genotype 3 HCV's short name is recorded as TIG3^[11].
• Telaprevir in Genotype 3 HCV's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[12].
• Telaprevir in Genotype 3 HCV's ClinicalTrials.gov ID is recorded as NCT02087111^[13].
• Telaprevir in Genotype 3 HCV's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+70'}^[14].
• Telaprevir in Genotype 3 HCV's research intervention is recorded as interferon-alpha^[15].
• Telaprevir in Genotype 3 HCV's clinical trial phase is recorded as phase IV clinical trial^[16].
• Telaprevir in Genotype 3 HCV's research site is recorded as Bradford Teaching Hospitals NHS Foundation Trust^[17].
• Telaprevir in Genotype 3 HCV's research site is recorded as Barts Health NHS Trust^[18].
• Telaprevir in Genotype 3 HCV's study type is recorded as interventional study^[19].